# Ziv-aflibercept Efficacy in Better Regulating AMD

> **NCT03423823** · PHASE2 · COMPLETED · sponsor: **Kapil Kapoor** · enrollment: 62 (actual)

## Conditions studied

- Wet Macular Degeneration
- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Ziv-Aflibercept 25 MG/ML [Zaltrap]
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT03423823
- **Lead sponsor:** Kapil Kapoor
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-07
- **Primary completion:** 2020-06-26
- **Final completion:** 2020-06-26
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423823, "Ziv-aflibercept Efficacy in Better Regulating AMD". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03423823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*